BRIEF-Merck To Acquire Cidara Therapeutics, Diversifying Its Portfolio To Include Late-Phase Antiviral Agent-March 2024-www.financetom.com

BRIEF-Merck To Acquire Cidara Therapeutics, Diversifying Its Portfolio To Include Late-Phase Antiviral Agent

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Merck To Acquire Cidara Therapeutics, Diversifying Its Portfolio To Include Late-Phase Antiviral Agent

Nov 14, 2025 4:10 AM

Nov 14 (Reuters) - Merck & Co Inc ( MRK ):

* MERCK TO ACQUIRE CIDARA THERAPEUTICS, INC., DIVERSIFYING

ITS

PORTFOLIO TO INCLUDE LATE-PHASE ANTIVIRAL AGENT

* MERCK & CO INC ( MRK ) - TO BUY CIDARA FOR $9.2 BILLION

* MERCK ( MRK ) & CO INC PROPOSED DEAL FOR $221.50 PER SHARE IN CASH

* MERCK & CO INC ( MRK ): UNDER TERMS OF MERGER AGREEMENT, MERCK ( MRK ),

THROUGH

A UNIT, WILL ACQUIRE ALL OF OUTSTANDING SHARES OF CIDARA

Source text:

Further company coverage:

Previous page： Unilever Dropped From X Lawsuit Over Advertising Boycott Next page： GM, Barclays sign long-term credit card partnership agreement

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Unilever Dropped From X Lawsuit Over Advertising Boycott

Oct 14, 2024

07:27 AM EDT, 10/14/2024 (MT Newswires) -- Unilever ( UL ) has resolved a dispute with the social media platform X, according to a court filing Friday. X said in a filing at a Texas federal court that it was dropping its claims against Unilever ( UL ), but its claims against all other defendants are unaffected by this dismissal....

GM, Barclays sign long-term credit card partnership agreement

Oct 14, 2024

Oct 14 (Reuters) - General Motors ( GM ) and Barclays ( JJCTF ) have signed a long-term credit card partnership agreement, the companies said on Monday. ...

Eli Lilly Says New Data Show Mirikizumab Achieves Histologic Response in Crohn's Disease

Oct 14, 2024

07:40 AM EDT, 10/14/2024 (MT Newswires) -- Eli Lilly ( LLY ) said Monday that data from a phase 3 study showed that more patients with moderately to severely active Crohn's disease achieved histologic response with mirikizumab treatment at week 52 compared with ustekinumab. The company said mirikizumab achieved statistically significant improvements across all histologic and histologic-endoscopic endpoints compared with...

Denmark's Lundbeck to buy Longboard Pharma in $2.6 billion deal

Oct 14, 2024

Oct 14 (Reuters) - Denmark's H Lundbeck A/S has agreed to buy Longboard Pharmaceuticals ( LBPH ) in a $2.6 billion deal to boost its pipeline of treatments for neuro-rare conditions, sending shares of the U.S.-based company up 43.9% in premarket trading. The companies said Lundbeck will acquire all of Longboard's shares for $60 per share, which represents a premium...